EXINIs investment in imaging biomarkers attracted

Lund, Sweden, 2013-10-30 09:29 CET (GLOBE NEWSWIRE) --  

EXINI attended the EANM (European Association of Nuclear Medicine) in Lyon October 19 to 23. At the congress, an updated version of EXINI bone ^BSI a software that provides diagnostic advice to be used in bone scintigraphy was launched.

Furthermore, three scientific studies regarding EXINI bone ^BSI and the calculation of Bone Scan Index (BSI) were presented at the congress. ¹

"The fact that three studies from important university hospitals and research centers was presented, confirms the large needs for imaging biomarkers within oncology imaging", says Magnus Aurell, CEO EXINI Diagnostics AB. ?

¹ The following studies were presented:

"Bone scan index as a biomarker of systemic metastatic bone involvement in prostate cancer can be easily obtained using an expert system" G. Berding?et al, Department of Nuclear Medicine, Hannover Medical School, Germany?

"Relation of Bone Scan Index and Bone Alkaline Phosphates in Prostate Cancer?Patients with Bone Metastases" H. Wakabayashi et al, Department of Nuclear Medicine, Kanazawa University Hospital, Japan

"Bone Scan Index: a strong predictor of outcome in metastatic hormone naive prostate cancer patients" J. Rasmussen et al, Department of Nuclear Medicine, Odense University Hospital, Denmark

(Abstracts are available at http://eanm13.eanm.org/)

For more information, please contact: Magnus Aurell, CEO Phone: +46 46 286 54 25 E-mail: magnus.aurell@exini.com

About EXINI Diagnostics AB (publ) EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its  own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 500 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.

         ________________________________________________________________________          EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden          Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com